p53 plays a crucial role in endothelial dysfunction associated with hyperglycemia and ischemia

Masataka Yokoyama, Ippei Shimizu, Ayako Nagasawa, Yohko Yoshida, Goro Katsuumi, Takayuki Wakasugi, Yuka Hayashi, Ryutaro Ikegami, Masayoshi Suda, Yusuke Ota, Sho Okada, Marcus Fruttiger, Yoshio Kobayashi, Masanori Tsuchida, Yoshiaki Kubota, Tohru Minamino

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

p53 is a guardian of the genome that protects against carcinogenesis. There is accumulating evidence that p53 is activated with aging. Such activation has been reported to contribute to various age-associated pathologies, but its role in vascular dysfunction is largely unknown. The aim of this study was to investigate whether activation of endothelial p53 has a pathological effect in relation to endothelial function. We established endothelial p53 loss-of-function and gain-of-function models by breeding endothelial-cell specific Cre mice with floxed Trp53 or floxed Mdm2/Mdm4 mice, respectively. Then we induced diabetes by injection of streptozotocin. In the diabetic state, endothelial p53 expression was markedly up-regulated and endothelium-dependent vasodilatation was significantly impaired. Impairment of vasodilatation was significantly ameliorated in endothelial p53 knockout (EC-p53 KO) mice, and deletion of endothelial p53 also significantly enhanced the induction of angiogenesis by ischemia. Conversely, activation of endothelial p53 by deleting Mdm2/Mdm4 reduced both endothelium-dependent vasodilatation and ischemia-induced angiogenesis. Introduction of p53 into human endothelial cells up-regulated the expression of phosphatase and tensin homolog (PTEN), thereby reducing phospho-eNOS levels. Consistent with these results, the beneficial impact of endothelial p53 deletion on endothelial function was attenuated in EC-p53 KO mice with an eNOS-deficient background. These results show that endothelial p53 negatively regulates endothelium-dependent vasodilatation and ischemia-induced angiogenesis, suggesting that inhibition of endothelial p53 could be a novel therapeutic target in patients with metabolic disorders.

Original languageEnglish
Pages (from-to)105-117
Number of pages13
JournalJournal of Molecular and Cellular Cardiology
Volume129
DOIs
Publication statusPublished - 2019 Apr 1

Fingerprint

Vasodilation
Hyperglycemia
Ischemia
Endothelium
Endothelial Cells
Experimental Diabetes Mellitus
Phosphoric Monoester Hydrolases
Breeding
Blood Vessels
Carcinogenesis
Genome
Pathology
Injections
Therapeutics

Keywords

  • Angiogenesis
  • Endothelium
  • Nitric oxide
  • Vascular disease

ASJC Scopus subject areas

  • Molecular Biology
  • Cardiology and Cardiovascular Medicine

Cite this

Yokoyama, M., Shimizu, I., Nagasawa, A., Yoshida, Y., Katsuumi, G., Wakasugi, T., ... Minamino, T. (2019). p53 plays a crucial role in endothelial dysfunction associated with hyperglycemia and ischemia. Journal of Molecular and Cellular Cardiology, 129, 105-117. https://doi.org/10.1016/j.yjmcc.2019.02.010

p53 plays a crucial role in endothelial dysfunction associated with hyperglycemia and ischemia. / Yokoyama, Masataka; Shimizu, Ippei; Nagasawa, Ayako; Yoshida, Yohko; Katsuumi, Goro; Wakasugi, Takayuki; Hayashi, Yuka; Ikegami, Ryutaro; Suda, Masayoshi; Ota, Yusuke; Okada, Sho; Fruttiger, Marcus; Kobayashi, Yoshio; Tsuchida, Masanori; Kubota, Yoshiaki; Minamino, Tohru.

In: Journal of Molecular and Cellular Cardiology, Vol. 129, 01.04.2019, p. 105-117.

Research output: Contribution to journalArticle

Yokoyama, M, Shimizu, I, Nagasawa, A, Yoshida, Y, Katsuumi, G, Wakasugi, T, Hayashi, Y, Ikegami, R, Suda, M, Ota, Y, Okada, S, Fruttiger, M, Kobayashi, Y, Tsuchida, M, Kubota, Y & Minamino, T 2019, 'p53 plays a crucial role in endothelial dysfunction associated with hyperglycemia and ischemia', Journal of Molecular and Cellular Cardiology, vol. 129, pp. 105-117. https://doi.org/10.1016/j.yjmcc.2019.02.010
Yokoyama, Masataka ; Shimizu, Ippei ; Nagasawa, Ayako ; Yoshida, Yohko ; Katsuumi, Goro ; Wakasugi, Takayuki ; Hayashi, Yuka ; Ikegami, Ryutaro ; Suda, Masayoshi ; Ota, Yusuke ; Okada, Sho ; Fruttiger, Marcus ; Kobayashi, Yoshio ; Tsuchida, Masanori ; Kubota, Yoshiaki ; Minamino, Tohru. / p53 plays a crucial role in endothelial dysfunction associated with hyperglycemia and ischemia. In: Journal of Molecular and Cellular Cardiology. 2019 ; Vol. 129. pp. 105-117.
@article{7f213c26afb94cca82a3d80f70d0c0f2,
title = "p53 plays a crucial role in endothelial dysfunction associated with hyperglycemia and ischemia",
abstract = "p53 is a guardian of the genome that protects against carcinogenesis. There is accumulating evidence that p53 is activated with aging. Such activation has been reported to contribute to various age-associated pathologies, but its role in vascular dysfunction is largely unknown. The aim of this study was to investigate whether activation of endothelial p53 has a pathological effect in relation to endothelial function. We established endothelial p53 loss-of-function and gain-of-function models by breeding endothelial-cell specific Cre mice with floxed Trp53 or floxed Mdm2/Mdm4 mice, respectively. Then we induced diabetes by injection of streptozotocin. In the diabetic state, endothelial p53 expression was markedly up-regulated and endothelium-dependent vasodilatation was significantly impaired. Impairment of vasodilatation was significantly ameliorated in endothelial p53 knockout (EC-p53 KO) mice, and deletion of endothelial p53 also significantly enhanced the induction of angiogenesis by ischemia. Conversely, activation of endothelial p53 by deleting Mdm2/Mdm4 reduced both endothelium-dependent vasodilatation and ischemia-induced angiogenesis. Introduction of p53 into human endothelial cells up-regulated the expression of phosphatase and tensin homolog (PTEN), thereby reducing phospho-eNOS levels. Consistent with these results, the beneficial impact of endothelial p53 deletion on endothelial function was attenuated in EC-p53 KO mice with an eNOS-deficient background. These results show that endothelial p53 negatively regulates endothelium-dependent vasodilatation and ischemia-induced angiogenesis, suggesting that inhibition of endothelial p53 could be a novel therapeutic target in patients with metabolic disorders.",
keywords = "Angiogenesis, Endothelium, Nitric oxide, Vascular disease",
author = "Masataka Yokoyama and Ippei Shimizu and Ayako Nagasawa and Yohko Yoshida and Goro Katsuumi and Takayuki Wakasugi and Yuka Hayashi and Ryutaro Ikegami and Masayoshi Suda and Yusuke Ota and Sho Okada and Marcus Fruttiger and Yoshio Kobayashi and Masanori Tsuchida and Yoshiaki Kubota and Tohru Minamino",
year = "2019",
month = "4",
day = "1",
doi = "10.1016/j.yjmcc.2019.02.010",
language = "English",
volume = "129",
pages = "105--117",
journal = "Journal of Molecular and Cellular Cardiology",
issn = "0022-2828",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - p53 plays a crucial role in endothelial dysfunction associated with hyperglycemia and ischemia

AU - Yokoyama, Masataka

AU - Shimizu, Ippei

AU - Nagasawa, Ayako

AU - Yoshida, Yohko

AU - Katsuumi, Goro

AU - Wakasugi, Takayuki

AU - Hayashi, Yuka

AU - Ikegami, Ryutaro

AU - Suda, Masayoshi

AU - Ota, Yusuke

AU - Okada, Sho

AU - Fruttiger, Marcus

AU - Kobayashi, Yoshio

AU - Tsuchida, Masanori

AU - Kubota, Yoshiaki

AU - Minamino, Tohru

PY - 2019/4/1

Y1 - 2019/4/1

N2 - p53 is a guardian of the genome that protects against carcinogenesis. There is accumulating evidence that p53 is activated with aging. Such activation has been reported to contribute to various age-associated pathologies, but its role in vascular dysfunction is largely unknown. The aim of this study was to investigate whether activation of endothelial p53 has a pathological effect in relation to endothelial function. We established endothelial p53 loss-of-function and gain-of-function models by breeding endothelial-cell specific Cre mice with floxed Trp53 or floxed Mdm2/Mdm4 mice, respectively. Then we induced diabetes by injection of streptozotocin. In the diabetic state, endothelial p53 expression was markedly up-regulated and endothelium-dependent vasodilatation was significantly impaired. Impairment of vasodilatation was significantly ameliorated in endothelial p53 knockout (EC-p53 KO) mice, and deletion of endothelial p53 also significantly enhanced the induction of angiogenesis by ischemia. Conversely, activation of endothelial p53 by deleting Mdm2/Mdm4 reduced both endothelium-dependent vasodilatation and ischemia-induced angiogenesis. Introduction of p53 into human endothelial cells up-regulated the expression of phosphatase and tensin homolog (PTEN), thereby reducing phospho-eNOS levels. Consistent with these results, the beneficial impact of endothelial p53 deletion on endothelial function was attenuated in EC-p53 KO mice with an eNOS-deficient background. These results show that endothelial p53 negatively regulates endothelium-dependent vasodilatation and ischemia-induced angiogenesis, suggesting that inhibition of endothelial p53 could be a novel therapeutic target in patients with metabolic disorders.

AB - p53 is a guardian of the genome that protects against carcinogenesis. There is accumulating evidence that p53 is activated with aging. Such activation has been reported to contribute to various age-associated pathologies, but its role in vascular dysfunction is largely unknown. The aim of this study was to investigate whether activation of endothelial p53 has a pathological effect in relation to endothelial function. We established endothelial p53 loss-of-function and gain-of-function models by breeding endothelial-cell specific Cre mice with floxed Trp53 or floxed Mdm2/Mdm4 mice, respectively. Then we induced diabetes by injection of streptozotocin. In the diabetic state, endothelial p53 expression was markedly up-regulated and endothelium-dependent vasodilatation was significantly impaired. Impairment of vasodilatation was significantly ameliorated in endothelial p53 knockout (EC-p53 KO) mice, and deletion of endothelial p53 also significantly enhanced the induction of angiogenesis by ischemia. Conversely, activation of endothelial p53 by deleting Mdm2/Mdm4 reduced both endothelium-dependent vasodilatation and ischemia-induced angiogenesis. Introduction of p53 into human endothelial cells up-regulated the expression of phosphatase and tensin homolog (PTEN), thereby reducing phospho-eNOS levels. Consistent with these results, the beneficial impact of endothelial p53 deletion on endothelial function was attenuated in EC-p53 KO mice with an eNOS-deficient background. These results show that endothelial p53 negatively regulates endothelium-dependent vasodilatation and ischemia-induced angiogenesis, suggesting that inhibition of endothelial p53 could be a novel therapeutic target in patients with metabolic disorders.

KW - Angiogenesis

KW - Endothelium

KW - Nitric oxide

KW - Vascular disease

UR - http://www.scopus.com/inward/record.url?scp=85061984300&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061984300&partnerID=8YFLogxK

U2 - 10.1016/j.yjmcc.2019.02.010

DO - 10.1016/j.yjmcc.2019.02.010

M3 - Article

VL - 129

SP - 105

EP - 117

JO - Journal of Molecular and Cellular Cardiology

JF - Journal of Molecular and Cellular Cardiology

SN - 0022-2828

ER -